دورية أكاديمية
International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study).
| العنوان: | International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study). |
|---|---|
| المؤلفون: | Rebuzzi SE; Medical Oncology Unit, Ospedale San Paolo, Savona, Italy.; Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy., Fornarini G; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Signori A; Department of Health Sciences (DISSAL), Section of Biostatistics, University of Genova, Genova, Italy., Buti S; Medical Oncology Unit, University Hospital of Parma, Parma, Italy. sebabuti@libero.it.; Department of Medicine and Surgery, University of Parma, Parma, Italy. sebabuti@libero.it., Procopio G; Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, Italy., De Giorgi U; Medical Oncology Department, IRCCS Istituto Romagnolo per lo studio dei tumori (IRST) 'Dino Amadori', Meldola, Italy., Pignata S; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy., Naglieri E; U.O. Oncologia, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy., Maruzzo M; IOV - IRCCS, Oncologia 1, Istituto Oncologico Veneto, Padova, Italy., Banna GL; Portsmouth Hospitals University NHS Trust, Portsmouth, PO6 3LY, UK.; Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, PO1 2UP, UK., Rescigno P; Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, UK.; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy., Messina C; Oncology Unit, ARNAS Civico, Palermo, Italy., Mattana A; IOV - IRCCS, Oncologia 1, Istituto Oncologico Veneto, Padova, Italy., Basso U; IOV - IRCCS, Oncologia 1, Istituto Oncologico Veneto, Padova, Italy., Bimbatti D; IOV - IRCCS, Oncologia 1, Istituto Oncologico Veneto, Padova, Italy. |
| المصدر: | BMC cancer [BMC Cancer] 2024 Jun 24; Vol. 24 (1), pp. 757. Date of Electronic Publication: 2024 Jun 24. |
| نوع المنشور: | Journal Article; Multicenter Study; Observational Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : BioMed Central, [2001- |
| مواضيع طبية MeSH: | Carcinoma, Renal Cell*/drug therapy , Carcinoma, Renal Cell*/mortality , Carcinoma, Renal Cell*/pathology , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/pathology , Kidney Neoplasms*/mortality , Registries*, Humans ; Prospective Studies ; Prognosis ; Male ; Female ; Retrospective Studies ; Middle Aged ; Aged |
| مستخلص: | Background: Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line therapy in all mRCC patients regardless of the International Metastatic RCC Database Consortium (IMDC) risk category, even though TKI monotherapy is still a therapeutic option in selected patients. However, comparisons between the different first-line treatment strategies are lacking and few real-world data are available in this setting. For this reason, the regimen choice represents an important issue in clinical practice and the optimal treatment sequence remains unclear. Methods: The REGAL study is a multicentric prospective observational study enrolling mRCC patients treated with first-line systemic therapy according to clinical practice in a real-world setting. A retrospective cohort of mRCC patients who received first-line systemic therapy from the 1st of January 2021 will also be included. The primary objective is to identify potential prognostic and predictive factors that could help guide the treatment choice; secondary objectives included the assessment of the prognostic performance of the novel prognostic Meet-URO score (IMDC score + neutrophil-to-lymphocyte ratio + bone metastases) compared with the IMDC score and the comparison between treatment strategies according to response and survival outcomes and toxicity profile. Discussion: Considering the high number of therapeutic first-line strategies available for mRCC, the identification of clinical prognostic and predictive factors to candidate patients to a preferable systemic therapy is still an unmet clinical need. The Meet-URO 33 study aims to provide a large-scale real-world database on mRCC patients, to identify the clinical predictive and prognostic factors and the different performances between the ICI-based combinations according to response, survival and toxicity. Trial Registration: CESC IOV 2023-78. (© 2024. The Author(s).) |
| References: | Crit Rev Oncol Hematol. 2023 Jan;181:103881. (PMID: 36427772) Ther Adv Med Oncol. 2020 Mar 18;12:1758835920907504. (PMID: 32215057) Cancer. 2020 Sep 15;126(18):4156-4167. (PMID: 32673417) N Engl J Med. 2019 Mar 21;380(12):1116-1127. (PMID: 30779529) Target Oncol. 2019 Aug;14(4):405-416. (PMID: 31301015) Eur J Cancer. 2020 Aug;135:203-210. (PMID: 32599410) Cancer Treat Rev. 2021 Nov;100:102295. (PMID: 34564043) Ther Adv Med Oncol. 2021 May 18;13:17588359211019642. (PMID: 34046089) Lancet Oncol. 2020 Dec;21(12):1563-1573. (PMID: 33284113) BMJ. 2022 Aug 30;378:e071108. (PMID: 36041749) Eur Urol Oncol. 2019 Sep;2(5):505-514. (PMID: 31377308) N Engl J Med. 2015 Nov 5;373(19):1803-13. (PMID: 26406148) ESMO Open. 2020 Nov;5(6):e001079. (PMID: 33246931) Cancer Immunol Immunother. 2021 Feb;70(2):265-273. (PMID: 32757054) Eur Urol Oncol. 2021 Oct;4(5):755-765. (PMID: 33757737) Eur J Cancer. 2021 Sep;154:120-127. (PMID: 34265504) Ann Oncol. 2021 Mar;32(3):422-423. (PMID: 33271289) Lancet Oncol. 2023 Mar;24(3):228-238. (PMID: 36858721) JCO Oncol Pract. 2022 Mar;18(3):187-196. (PMID: 34529499) Hematol Oncol Clin North Am. 2023 Oct;37(5):943-949. (PMID: 37258352) Cancer Treat Rev. 2022 May;106:102377. (PMID: 35313232) Lancet Oncol. 2022 Jul;23(7):888-898. (PMID: 35688173) Cancers (Basel). 2020 Jan 07;12(1):. (PMID: 31936065) |
| فهرسة مساهمة: | Keywords: Clinical practice; IMDC score; Immune checkpoint inhibitor; Immunotherapy; Meet-URO score; Metastatic renal cell carcinoma; Prospective; Real-world; Retrospective |
| تواريخ الأحداث: | Date Created: 20240624 Date Completed: 20240624 Latest Revision: 20240927 |
| رمز التحديث: | 20240927 |
| مُعرف محوري في PubMed: | PMC11194925 |
| DOI: | 10.1186/s12885-024-12319-1 |
| PMID: | 38914928 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1471-2407 |
|---|---|
| DOI: | 10.1186/s12885-024-12319-1 |